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Abstract
COVID-19 pandemic is plaguing the world and representing the most significant stress test for many national healthcare systems
and services, since their foundation. The supply-chain disruption and the unprecedented request for intensive care unit (ICU) beds
have created in Europe conditions typical of low-resources settings. This generated a remarkable race to find solutions for the
prevention, treatment and management of this disease which is involving a large amount of people. Every day, new Do-It-
Yourself (DIY) solutions regarding personal protective equipment and medical devices populate social media feeds. Many
companies (e.g., automotive or textile) are converting their traditional production to manufacture the most needed equipment
(e.g., respirators, face shields, ventilators etc.). In this chaotic scenario, policy makers, international and national standards
bodies, along with the World Health Organization (WHO) and scientific societies are making a joint effort to increase global
awareness and knowledge about the importance of respecting the relevant requirements to guarantee appropriate quality and
safety for patients and healthcare workers. Nonetheless, ordinary procedures for testing and certification are currently questioned
and empowered with fast-track pathways in order to speed-up the deployment of new solutions for COVID-19. This paper shares
critical reflections on the current regulatory framework for the certification of personal protective equipment. We hope that these
reflections may help readers in navigating the framework of regulations, norms and international standards relevant for key
personal protective equipment, sharing a subset of tests that should be deemed essential even in a period of crisis.
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1 Introduction
As of early April 2020, the world is stricken by the recent
pandemic outbreak [1] of a new strain of Coronavirus, previ-
ously unknown to mankind, denominated Severe Acute
Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). This
virus is part of the family of the coronaviruses, which are
viruses commonly affecting mammals and birds. Although
the respiratory tract infections on humans caused by this fam-
ily of viruses are usually common colds (Human Coronavirus
229E, Human Coronavirus NL63, Human Coronavirus
OC43, and Human Coronavirus HKU1), sometimes they be-
get viral pneumonia and rarely they can be the cause of a
severe acute respiratory syndrome (SARS) (SARS-CoV,
MERS-CoV, and SARS-CoV-2) [2]. SARS-CoV-2 causes a
disease, better known as COVID-19 (CO for Corona, VI for
Virus, D for disease and 19 for the year in which it was iden-
tified), with symptoms spanning from mild (e.g., fever, tired-
ness, dry and continuous cough, and shortness of breath, di-
arrhoea, and sore throat [3, 4]) to serious (e.g., viral pneumo-
nia and multi-organ failure [5, 6]). SARS-CoV-2, similarly to
other viruses [7], seems to have spilled over to humans from
wild animals [8]. As a consequence, the human immune sys-
tem, having never been in contact with such a virus, lacks the
ability to fight against the pathogen [7], which can have
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particularly dangerous effects on subjects with already weak
immune systems, or immunosuppressed or elderly subjects
with existing preconditions. Based on the current information,
the virus has been classed as a Hazard Group 3 (HG3) patho-
gen [9] and the World Health Organization (WHO) has stated
that laboratory tests and practices should follow biosafety lev-
el 3 guidelines [10].
The COVID19 outbreak impact on European countries was
twofold. First, the supply chain of personal protective equip-
ment (PPE), medical devices (MDs), consumables and spare
parts revealed its frailty in its dependence on China’s capabil-
ity to produce them, severally hindered by the lockdown since
January 2020. Second, this world pandemic has been causing
an unprecedented demand of hospitalizations, especially in
intensive care units (ICUs), since its early stages. This set
off a chain reaction affecting a number of other routine hospi-
talizations (e.g., elective surgeries), which were postponed
giving priority to ICU beds in terms of resources (spaces,
personnel, equipment) Moreover, healthcare staff is highly
exposed to the risk of catching COVID-19 themselves, due
to the inner nature of their daily routine, which exposes them
to physical contact with patients. The combination of these
factors has created in Europe de facto conditions that are usu-
ally typical of ‘low-resource settings’, generating havoc
among all the countries, independently from their wealth
level.
The combination of a frail supply-chain and an unprece-
dented demand of ICU beds demonstrated the extent to which
countries were not prepared to tackle global disasters, such as
the current pandemic.
This is particularly evident in Europe, where many
healthcare systems (e.g., France, Italy, Spain and the UK),
being rated among the best ones in the world [11], are being
heavily overburdened by the ever-increasing number of pa-
tients needing hospitalization or intensive care [12–15]. The
national health systems, in fact, lack essential resources1 for
dealing with COVID-19, including MDs (e.g. surgical masks,
ventilators, infusion pumps), PPEs [16] and healthcare per-
sonnel (who is being reduced by the disease itself).
For the first time after decades, the progressive scarcity of
devices, equipment and resources has raised also in high-
income countries the problem of resource allocation and
prioritisation. The latter could expose a part of the population,
probably the most disadvantaged individuals, to further diffi-
culties in accessing healthcare services [17].
The urgent need for equipment directly affects the role of
clinical engineers, professionals who are in charge of verify-
ing that all the medical and electro-medical devices are com-
pliant with the essential requirements imposed by the national
laws, before authorising their use in hospital settings. In
Europe, this means compliance with the European framework
of directives and regulations certified by the presence of the
CE mark. Strictly following international standards is the reg-
ular path chosen by the manufacturers in order to guarantee
the compliance of their products to the above-mentioned re-
quirements, in terms of performances and safety. The current
situation has highlighted the flaws of the regulations. For in-
stance, the non-universality of regulations, norms and interna-
tional standards is clearly evident in these situations of emer-
gency. The problem of non-universality of technical norms is
well-known in the context of low-resources settings, especial-
ly in the context of Low- and Middle-Income Countries
(LMICs) as highlighted by the authors of this paper who have
been extensively acting to overcome this issue [18, 19]. The
COVID19 pandemic, is dramatically demonstrating that this
limit is paramount also in high-income countries during emer-
gencies. The international standards, indeed, proved to be of-
ten too generic and demanding, resulting difficult to be imple-
mented in many countries, in terms of time, costs and overall
effort required, thus jeopardizing a prompt response to emer-
gencies. This is everyday evidence in lower-income countries,
and it is becoming now clear also in high-income ones.
In this critical context, we have joined our efforts to write
this manuscript in order to share our considerations on the
necessity of identifying a set of minimum requirements to test
PPEs for use in hospitals during the COVID19 pandemic. We
hope this contribution may be relevant for the readers, helping
them navigating the variegated context of PPEs regulatory
framework. The proposed approach reflects a minimum set
of tests that should always be considered despite the waivers
issued by several states. This discussion should then be con-
tinued, once this crisis will be over, especially with regard to
lower-income countries, where the inadequacy of internation-
al norms is clear also in everyday conditions.
2 PPE regulation in EU and its inadequacy
for COVID-19
The first European directive on the design, the manufacture
and the marketing of PPEs was published in December 1989,
exactly 30 years before SARS-CoV-2 was first identified in
China (Directive 89/686/EEC). This Directive was superseded
in 2016 by Regulation (EU) 2016/425, which outlines legal
obligations in order to guarantee the highest quality and effi-
ciency of the PPEs circulating in the EU internal market. The
compliance with such regulation is assured by the CE mark-
ing. As per semantics, the change from directives to regula-
tions was not trivial and implied a tougher and more harmo-
nized approach. Directives, in fact, are EU instruments requir-
ing member states to legislate accordingly and enforce them at
a National level by relevant laws with a certain flexibility.
Vice versa, EU Regulations are simultaneously enforced in
1 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/
technical-guidance/covid-19-critical-items
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each member state after a transitional period, imposing clear
and detailed common rules, which do not give room for di-
vergent transpositions by member states [20].
The Regulation (EU) 2016/425 itself refers to harmonized
standards, developed by a recognized European Standards
Organizat ion (e.g. , the European Committee for
Standardization (CEN)) as a way in which manufacturers or
Notified Bodies can assess the conformity of a product. As of
Personal Eye Protection and Respiratory Protective Devices,
EN166:2001 and EN 149:2001 + A1:2009 are the respective
harmonized standards.
The pathway that manufacturers can take for achieving
the CE Marking of PPE are different, depending on the PPE
risk-category. For PPE used in low-risk conditions, manu-
facturers can rely on internal labs and tests to demonstrate
that their products are compliant with the harmonised stan-
dards requirements, issuing self-certifications. When deal-
ing with protection against SARS-CoV-2 virus, the PPEs
are framed in the highest risk class (class II or III), requiring
the involvement of external notified bodies. Notified Bodies
are appointed under the Article 28 of Regulation (EU)
2016/425, and their responsibilities include confirming that
PPE have an adequate level of health and safety in accor-
dance with the essential requirements laid down for that
product in harmonised standards. According to the number
of PPE produced, Notified Bodies may be requested to re-
peat this test several times per year. This may include testing
few samples that manufactures send to the Notified Body, as
well as inspections in the manufacturing farms. A key point
is that there is a series of tests that need to be performed
according to the relevant standards, depending on the type
of device and equipment, to prove that the designed solu-
tions fulfil the minimum requirements in terms of perfor-
mance and safety. This series of tests is not specific for
hospital settings, but it is general, aiming at including all
the working conditions to which PPE could be exposed,
including testing the robustness of PPE after having been
exposed to extreme temperatures (e.g., 70 °C), which are
never reached in hospitals due to harmonised standards for
medical locations.
Therefore, when dealing with general standards, their
generality becomes a too stringent constraint in emergency
situations. For example, PPEs such as face shields or parti-
cle filtering face masks (e.g., FFP2 or FFP3 masks) are also
(and more often) required in settings other than hospitals,
such as in carpentry or soldering activities, in conditions
very different from the ones needed by hospital settings.
The tests required by the international norms reflect these
extreme working conditions, which are different from the
ones that can be found in hospitals. Some national standards
developing organisations and some notified bodies, aware
of the fact that requiring redundant tests is not strictly nec-
essary in conditions of emergency, reconsidered the whole
procedure for testing PPEs and reduced it to a subset of
essential tests and minimum requirements that should be
met for the use in a COVID-19 hospital department. A sim-
ilar approach to the one described by Badnjevic et al. [21]
can be used for standardised procedures with minimum re-
quirements for assessing medical equipment in healthcare
settings in situations of crisis and emergency.
Confirming this criticism, on the 13th March 2020 the EU
Commission published the Recommendation EU 2020/403
(non-legislative act), providing guidance for conformity as-
sessment and market surveillance procedures within the con-
text of the COVID-19 threat. This recommendation has
proved the resiliency of the European Commission and its
outstanding capability to react to crisis, while confirming the
inadequacy of European Regulation for crises and scarce re-
source scenarios.
Amid this widespread confusion, the scientific community
has to make clear the fact that, especially during a crisis, PPE
should meet the highest possible quality standards, in accor-
dance with the ALARP (As Low As Reasonably Possible)
risk management principle [22].
3 Amatorial solutions and the importance
of international standards and CE marking
The importance of meeting high-quality standards, guarantee-
ing the efficiency of medical devices and equipment and the
safety of their users, is evident now more than ever. During
this pandemic, we are witnessing growing proliferation of
amatorial initiatives (i.e., quick fixes) aiming at providing
for the above-mentioned needs. These initiatives, amplified
through social media, although certainly driven by good in-
tentions, may beget a series of solutions potentially as harmful
as the problem they are trying to solve, if not properly
mentored. The innumerable solutions one can come across
on the internet span from using baking paper to reproduce a
(surgical!) face mask to 3D printing respirators using cotton
filters, claiming that they are effective in filtering the virus.
The lack of any risk assessment, albeit minimal, poses major
risks for the user. Using materials from vacuum cleaner filters
to realize filtering face masks, for example, could be a threat
for the user’s safety, in case of presence of dangerous glass
microfibers [23].
Also in this context, regulations and standards are essen-
tial, as they sum up the state of the art, resulting from a series
of field experiences, aimed at guiding the manufacturer in
designing and producing devices with high levels of safety.
In this regard, visual inspections performed by experienced
technicians are the first approaches that can be used to eval-
uate if the obtained prototype is safe-by-design. For exam-
ple, even a small abrasion or defect due to sub-optimal ma-
terials or inappropriate manufacturing processes, can
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potentially lead to discomfort and skin irritation or lesions
in the long run. This possibility, potentially dangerous in
normal working conditions, is even more risky in extraor-
dinary working conditions. In severe working conditions
(due to extended/more frequent shifts for lack of personnel
and to stressful conditions), mistakes or distractions are
even more likely. A robust design is thought to be resilient
to these conditions as well.
3.1 The review of standards in situations
of emergency – A case study in UK
The UK Office for Product Safety and Standards (OPSS) has
been working with manufacturers to understand where regu-
latory requirements were preventing them from delivering the
products the public and NHS needed, offering continuously
updates and guidance.
The 10th of April 2020, the OPSS' position is that manu-
facturers can deploy PPE provided that:
& it meets the essential safety requirements, and
& conformity assessment procedures have been started via a
Notified Body, even if the conformity assessment, “in-
cluding affixing of CE marking procedures”, has not been
completed.
The OPSS has also issued an official letter to UK Notified
Bodies providing further guidance on the European
Commission Recommendation (EU 2020/403) and urging
them to prioritise the conformity assessment of PPEs neces-
sary for protection in the context of the COVID-19 and
requesting this work to be conducted swiftly. With this letter,
notified bodies were also allowed to test the products using
other than harmonised standards, nominally World Health
Organisation recommendations.
UK Notified Bodies reacted promptly prioritising such
tests, aiming at assessing essential safety requirements spe-
cifically thinking to NHS workers during the COVID-19
pandemic. As a result, PPEs can now be tested much faster
(e.g., in 1 week for face shields), for one third of the usual
cost circa and with also a reduced number of samples to be
sent for the tests. Certainly, this has been a prompt and
functional response. However, once this COVID crisis will
be overcome, there should be a wider discussion on how to
make norms and regulations intrinsically more flexible so as
to always allow rapid interventions to ever-changing situa-
tions and to be inclusive of many different specificities. This
could potentially be achieved either by including some de-
fault waivers which could allow modifications in case of
need, or by reformulating the way the regulations are con-
ceived, basing the new ones on a better-defined and effec-
tive universality.
3.1.1 Face shields
Face shields (aka visors) are part of a family of devices named
personal eye protective equipment, as defined in EN
166:2001. According to EN ISO 4007:2018, the term “protec-
tor” (3.5.1.1) for purposes of eye and face protection includes
eye protectors (3.5.1.2), eye guards (3.5.1.4), face protectors
(3.5.1.5), face screens/shields (3.5.1.6) and more (i.e. goggles,
hand shields, protective masks, spectacles, visors).
As afore mentioned EN 166 provides for a series of tests for
the evaluation of face shields that are inclusive of any possible
future use, including the industrial environment in which the
worker is at high risk of injuring his/her eyes and/or face with
splinters or electric arcs. However, to respond to the urgent
needs related to the COVID-19, national standards bodies
have reduced the number and type of essential tests to be
performed on face shields to be used in healthcare settings
for COVID-19. This fits perfectly the concept of norms as
technical means to reach the state of the art. Technical stan-
dards are never mandatory. The authors of this paper have
been in touch with different international experts and stan-
dards bodies investigating what type of test they would carry
out on PPE in this situation of emergency. Based on these
discussions and on the subset of tests individuated by the
standards bodies, the authors of this paper drafted their own
subset of suggested tests. Table 1 summarizes the tests that the
authors of this paper believe to be essential for face shields
that are to be used as an additional protection by healthcare
workers in this pandemic. EN 166 refers to EN 167:2002 for
some test specifications; however, EN167 was recently super-
seded by EN ISO 18526:2020. Therefore, the authors created
Table 1 inserting the links to the correct clauses in the new
standard, where applicable.
3.1.2 Filtering half masks
Filtering half masks to protect against particles are part of a
family of equipment named “respiratory protective devices”,
which are regulated by EN 149:2001 + A1:2009. They are
defined as respiratory protective devices that consist substan-
tially of filter material or comprise a facepiece in which the
main filter(s) form an inseparable part of the device. These
devices can be provided with valves for inspiration and exha-
lation. Depending on their filtering power, they can be desig-
nated as FFP1, FFP2 and FFP3. FFP2 and FFP3 half masks,
which are suggested as a protection against COVID-19 [24],
belong to category III and require, for CE marking, a certifi-
cate from and external notified body, issued after exams on the
product technical documentation and tests on the product it-
self, as stated in the European Regulation 2016/425.
As per the face shields, also the tests enlisted for these
devices are designed taking into account all the most disparate
conditions of use. The authors of this paper, after having
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Table 1 The subset of tests (EN 166) deemed essential to evaluate
personal eye protection equipment for COVID-19
Performance
requirement
Test method clause Requirement
General construction
(Section 6.1 EN
166:2002)
Visual inspection and
manufacturer’s
certificates
Eye-protectors shall be
free from projections,
sharp edges or other
defects which are
likely to cause
discomfort or injury
during use.
Materials (6.2) Visual inspection and
manufacturer’s
certificates
No parts of the
eye-protector which
are in contact with
the wearer shall be
made of materials
which are known to
cause any skin irrita-
tion.
Headbands (6.3) By measuring Headbands, when used
as the principal
means of retention,
shall be at least
10 mm wide over
any portion which
may come into
contact with the
wearer’s head.
Headbands shall be
adjustable or
self-adjusting.
Field of vision
(7.1.1)
The size of the field of
vision is defined in
conjunction with the
appropriate
head-form described
in clause 17 of EN
168:2001.
The test shall be carried
out in accordance
with clause 18 of EN
168:2001.
Eye-protectors shall
exhibit a minimum
field of vision
defined by the two
ellipses when placed
and centered at a
distance of 25 mm
from the surface of
the eyes of the
appropriate
head-form. The
horizontal axis shall
be parallel to and
0,7 mm below the
height of the line
connecting the
centres of the two
eyes.
The horizontal length of
the ellipses shall be of
22.0 mm, the vertical
width of the ellipses
shall be 20.0 mm.
The centre distance
of the two ellipses
shall be
d = c + 6 mm, where
c is the pupillary
distance. The
pupillary distance is
64 mm for the
medium head-form
Table 1 (continued)
Performance
requirement
Test method clause Requirement
and 54 mm for the
small head-form, if
not specified differ-
ently by the
manufacture.
Spherical, astigmatic
and prismatic
refractive powers
(7.1.2.1)
The refractive powers of
oculars shall be
measured by the
reference methods
specified in clause 6
of EN ISO
18526-1:2020. If,
during measurement
using the telescope, a
doubling or other
aberration of the
image is observed,
then the test sample
shall be subjected to
further examination
using the test method
described in 6.3 of
EN ISO
18526-1:2020
The permissible
tolerances for oculars
without corrective
effect are given in the
Clause 7.1.2.1.2 of
EN166.
Transmittance –
oculars without
filtering action
(7.1.2.2–1)
Clause 6 of EN ISO
18526-2:2020
Oculars intended to
protect the eyes
against mechanical or
chemical hazards
only, and cover
plates, shall have a
luminous
transmittance greater
than 74.4%.
Diffusion of light
(7.1.2.3)
Clause 14 of EN ISO
18526-2:2020
The max value of the
reduced luminance
factor shall be
0.50 cd/(m2*lx) for
all the other oculars.
Quality of material
and surface
(7.1.3)
Clause 6.6 of EN ISO
18526-3:2020
Except for a marginal
area 5 mm wide,
oculars shall be free
from any significant
defects likely to
impair vision in use,
such as bubbles,
scratches, inclusions,
dull spots, pitting,
mould marks,
scouring, grains,
pocking, scaling and
undulation.
Minimum
robustness
(7.1.4.1)
Clause 3.1 of EN
168:2001
The 7.1.4.1 requires
performing an impact
test with a 22 mm
nominal diameter
steel ball, impacting
with a force of
(100 ± 2) N.
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discussed with different national standards bodies, similarly to
their approach with face shields, summarised in Table 2 the
tests that they believe to be essential for this piece of equip-
ment to be used by healthcare workers in this pandemic, be-
yond the biocompatibility evaluation.
4 Similarities between the COVID-19
pandemic and low-resource settings
COVID-19 pandemic and low-resource settings have deep
differences, but also many commonalities. Low-resource set-
tings are common in LMICs, but also exist in rural and remote
areas of many high-income ones. Contrary to the common
belief, the main problem of low-resource settings lays beyond
the lack of funding. Several studies have in fact highlighted
the fact that if this had been the main problem, donations
would have solved it [19, 25]. Conversely, modern medicine
requires much more than budget, as it is evident especially in
the remit of medical devices and equipment, included PPE. In
fact, low-resource settings are often characterised by the lack
of clinical knowledge, lack of specialised clinical personnel
and technical staff, scarcity of medical devices, drugs and
spare parts due to a jeopardised supply-chain [19, 26]. As
argued above, COVID-19 has simultaneously hindered the
Table 1 (continued)
Performance
requirement
Test method clause Requirement
On so testing the
following defects
shall not occur:
a) ocular fracture: an
ocular shall be
considered to have
fractured if it cracks
through its entire
thickness into two or
more pieces, or if
more than 5 mg of
the ocular material
becomes detached
from the surface
away from the one in
contact with the ball,
or if the ball passes
through the ocular;
b) ocular deformation:
an ocular shall be
considered to have
been deformed if a
mark appears on the
white paper on the
opposite side to the
one on which the
force is applied.
Note: in period of crisis
such as the COVID,
this should be at least
tested using realistic
simulations
Resistance to
corrosion (7.1.6)
Clause 6.9 of EN ISO
18526-3:2020
After the test, all metal
parts of the
eye-protector shall
display smooth
surfaces, free from
corrosion, when they
are examined by a
trained observer.
Note: This should be
extended to plastic
parts considering the
sterilization
processes and
substances (e.g., after
cleaning visibility
should not be
compromised)
Resistance to
ignition (7.1.7)
Clause 6.10 of EN ISO
18526-3:2020
Eye-protectors shall be
considered to be
satisfactory if no part
of the eye-protector
ignites or continues
to glow after removal
of the steel rod.
Protection against
(droplets) and
Clause 12 of EN
168:2001
Face-shields cover the
eye-region rectangle
of the appropriate
Table 1 (continued)
Performance
requirement
Test method clause Requirement
splashes of liquid
(7.2.4)
head-form as de-
scribed in 10.2.2.2 of
EN 168:2001 as
assessed in accor-
dance with 10.2 of
EN 168:2001.
Additionally,
face-shields for pro-
tection against
splashes of liquids
shall have a viewing
area with a minimum
vertical centre-line
depth of 150 mm
when mounted in the
appropriate housing.
Lateral protection
(7.2.8)
Clause 6.4 of EN ISO
18526-3:2020
Eye-protectors claimed
to provide lateral
protection shall pass
the lateral region
coverage assessment
Resistance to
fogging (7.3.2)
Clause 6.11 of EN ISO
18526-3:2020
If oculars are described
as resistant to fogging
they shall remain free
from fogging for a
minimum of 8 s
when tested.
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Table 2 The subset of tests (EN 149:2001 + A1:2009) deemed essential
to evaluate respiratory protective devices for COVID-19
Performance
requirement
Test method clause Requirement
Visual inspection
(Section 7.3 EN
149:2001 + A1:200-
9)
The visual inspection
is carried out where
appropriate by the
test house prior to
laboratory or
practical
performance tests
(Clause 8.2).
Packaging (7.4) The visual inspection
is carried out where
appropriate by the
test house prior to
laboratory or
practical
performance tests
(Clause 8.2).
Particle filtering half
masks shall be
offered for sale
packaged in such a
way that they are
protected against
mechanical damage
and contamination
before use.
Cleaning and
disinfecting (7.6)
Testing shall be done
in accordance with
Clause 8.4 and
Clause 8.5. With
reference to 7.9.2,
after cleaning and
disinfecting the
re-usable particle
filtering half mask
shall satisfy the
penetration require-
ment of the relevant
class. Testing shall
be done in accor-
dance with Clause
8.11.
After cleaning and
disinfecting the
re-usable particle
filtering half mask
shall satisfy the
penetration require-
ment of the relevant
class.
If the particle filtering
half mask is
designed to be
re-usable, the
materials used shall
withstand the
cleaning and
disinfecting agents
and procedures to be
specified by the
manufacturer.
Practical performance
(7.7)
The particle filtering
half mask shall
undergo practical
performance tests
under realistic
conditions.
2 particle filtering half
masks shall be
tested as received in
accordance with
Clause 8.4.
During the tests the
particle filtering half
mask shall be
subjectively
assessed by the
wearer and after the
test, comments on
the following shall
be recorded:
a) head harness
comfort;
These general tests
serve the purpose of
checking the
equipment for
imperfections that
cannot be
determined by the
tests described
elsewhere in this
standard.
b) security of
fastenings;
c) field of vision;
d) any other comments
reported by the
wearer on request.
Where practical
performance tests
show the apparatus
has imperfections
related to wearer’s
acceptance, the test
house shall provide
Table 2 (continued)
Performance
requirement
Test method clause Requirement
full details of those
parts of the practical
performance tests
which revealed
these imperfections.
Total inward leakage
(7.9.1)
The laboratory tests
shall indicate that
the particle filtering
half mask can be
used by the wearer
to protect with high
probability against
the potential hazard
to be expected. The
total inward leakage
consists of three
components: face
seal leakage,
exhalation valve
leakage (if
exhalation valve
fitted) and filter
penetration.
At least 5 specimens
shall be tested as
received in
accordance with
Clause 8.5.
All samples must
achieve the
specifics.
All individual exercise
results tests shall be
not greater than 11%
(FFP2) (5% for
FPP3) and, in
addition, all arith-
metic means for the
total inward leakage
shall be not greater
than 8% (FFP2) (2%
for FFP3).
Penetration of filter
material (7.9.2)
At least 3 samples shall
be tested as received
for NaCl and
paraffin oil (PO) for
3 min in accordance
with Clause 8.11.
The maximum
penetration of test
aerosol shall be:
• 6% for both PO and
NaCl for FFP2
• 1% for both PO and
NaCl for FFP3
Carbon dioxide
content of the
inhalation air (7.12)
At least 3 particle
filtering half masks
shall be tested in
accordance with
Clause 8.7.
The carbon dioxide
content of the
inhalation air (dead
space) shall not
exceed an average
of 1.0% (by
volume).
Head harness (7.13) Testing shall be done
in accordance with
Clause 8.4 and 8.5.
The head harness shall
be designed so that
the particle filtering
half mask can be
donned and
removed easily. The
head harness shall
be adjustable or
self-adjusting and
shall be sufficiently
robust to hold the
particle filtering half
mask firmly in posi-
tion and be capable
of maintaining total
inward leakage re-
quirements for the
device.
Field of vision (7.14) Testing shall be done
in accordance with
Clause 8.4.
The field of vision is
acceptable if
determined so in
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supply-chain, increased the ICU hospitalization demand and
reduced staff. This created de facto conditions that are quite
common in low-resource settings, especially in LMICs.
The COVID-19 pandemic demonstrated the lack of knowl-
edge and lack of preparedness of many high-income coun-
tries, aggravated by the slowness in perceiving the complexity
of the situation faced by other countries, affected by the
COVID-19 months in advance. For instance, before facing
the COVID-19 outbreak in Milan metropolitan area, Italian
authorities and experts of virology failed to understand the
complexity of the situation in China and failed to acknowl-
edge the great work done by Chinese colleagues. The same
inertia has affected many north European Countries, which
failed to appreciate the complexity of the COVID-19 disaster
in Italy, despite the prompt response of Regional Institutions,
especially in the South. While we write this paper, it seems
that the USA reaction is again demonstrating some degree of
inertia, failing again to acknowledge the severity of the situa-
tion in many European Countries, despite the effort that those
countries are putting into the limitation of this pandemic.
Despite the deep differences, the shift of methodology from
low-resource settings to the COVID-19 pandemic response
may help speeding-up the response to the emergency, also in
high-income countries. After all, shifting from domains where
we lack solutions to a domain where we have established
methods and tools has been one of the most powerful engi-
neering solutions. An example could be the application of
transformations such as Laplace transform to differential
problems, bringing them in a domain where the equations
become algebraic and can be easily solved in analytic form,
and then shifted in the original domain using an anti-
transform.
5 Conclusion
The COVID19 outbreak has shown clearly the unsuitability of
PPEs’ regulatory framework, body of norms, and international
standards to extreme conditions. This was evident to the pro-
fessionals working in low-resource settings, such as low- and
middle-income countries and it emerged now powerfully also
for high-income countries during the COVID-19 pandemic.
The European regulatory framework evolved in the 1990s,
mainly to protect European manufacturers from the unsustain-
able competition from manufacturers producing abroad. This
evolution has been also driven by the manufacturers’ need to
produce PPEs for the widest market possible, therefore fol-
lowing the principle of generalism (i.e., PPE tested to be used
in any context) as opposed to particularism (i.e., PPE tested to
be used in a specific context, such as nurses working in hos-
pital wards). The prevalence of generalism over particularism
resulted in a loss of universality, and in the fact that norms that
can be sustained in normal conditions, at least by high-income
countries, become unsustainable in times of crisis. These
norms, which are often assumed as standards de facto also in
many non-EU countries (e.g. in many African countries), are
clearly not sufficiently universal for the contexts of low- and
middle-income countries.
In this manuscript, two examples of simplified protocols
starting from existing harmonized norms are presented and
discussed. Similar exemplifications are currently accepted by
European notified bodies in some EU Countries and could
guide the realisation of tests in low- and middle-income coun-
tries. Starting from this unprecedented crisis, high-income
countries will have to reconsider the nature of this regulatory
framework and of these norms and international standards.
The main lessons that the biomedical and clinical engineering
community should learn from this terrible experience is that
there is a major need for an evidence-based regulatory frame-
work, responding to the need of lead and lay users, rather than
those of the market itself.
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Table 2 (continued)
Performance
requirement
Test method clause Requirement
practical
performance tests.
Breathing resistance
(7.16)
At least 3 samples shall
be tested as received
in accordance with
Clause 8.9.
The maximum
permitted
resistances per
volumetric flow rate
for FFP2 are:
• 30 l/min – 0.7 mbar
(inhale)
• 95 l/min – 2.4 mbar
(inhale)
• 160 l/min – 3.0 mbar
(exhale)
For FFP3 are:
• 30 l/min – 1.0 mbar
(inhale)
• 95 l/min – 3.0 mbar
(inhale)
• 160 l/min – 3.0 mbar
(exhale)
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